title: INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy-a Randomised Intervention Trial with losartan).
abstract: Early pharmacological interventions on transgenic models of hypertrophic cardiomyopathy (HCM) using angiotensin receptor blockers (ARBs) may be effective in preventing development of clinical phenotype or causing phenotype regression in early stages of disease. In the clinical setting, however, the effects of ARBs on HCM phenotype have been less consistent. INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy-a Randomised Intervention Trial with losartan) was designed to assess the effect of 100 mg of losartan in promoting the regression of LV hypertrophy in HCM. The primary end-point of the study was the reduction in LV mass assessed by MRI or computed tomography. After 12 months, no reduction in LV mass was observed in the losartan arm, and there was no difference in LV mass change with the placebo arm. The same was true for all secondary endpoints. The implications of these findings are discussed in the light of further, ongoing study targeting the HCM phenotype.
authors.affiliation: Referral Center for Myocardial Diseases, Careggi University Hospital, Florence, Italy.
authors.forename: Iacopo
authors.initials: I
authors.lastname: Olivotto
authors.affiliation: Center for Inherited Cardiovascular Disease, Stanford University, California, USA.
authors.forename: Euan A
authors.initials: EA
authors.lastname: Ashley
references.citation: Circulation. 2005 May 17;111(19):2503-8
references.pmid: 15867172
references.citation: JAMA. 1996 May 15;275(19):1507-13
references.pmid: 8622227
references.citation: Lancet Diabetes Endocrinol. 2015 Feb;3(2):123-31
references.pmid: 25533774
references.citation: JACC Heart Fail. 2013 Dec;1(6):480-7
references.pmid: 24621999
references.citation: Eur Heart J. 2012 Jul;33(14):1724-33
references.pmid: 22719025
references.citation: Glob Cardiol Sci Pract. 2012 Jul 03;2012(1):9
references.pmid: 25610840
references.citation: Glob Cardiol Sci Pract. 2013 Nov 01;2013(3):243-8
references.pmid: 24689025
references.citation: Cardiovasc Res. 2015 Apr 1;105(4):449-56
references.pmid: 25631582
references.citation: Science. 2013 Oct 4;342(6154):111-4
references.pmid: 24092743
references.citation: Am J Cardiol. 2005 Dec 1;96(11):1563-7
references.pmid: 16310441
references.citation: Circulation. 2010 Oct 19;122(16):1562-9
references.pmid: 20921440
references.citation: Int Heart J. 2007 Nov;48(6):715-24
references.pmid: 18160763
references.citation: J Mol Diagn. 2009 Jan;11(1):35-41
references.pmid: 19074594
references.citation: EMBO Mol Med. 2013 Jul;5(7):1128-45
references.pmid: 23716398
references.citation: J Am Coll Cardiol. 2012 Sep 4;60(10):922-9
references.pmid: 22935464
references.citation: JACC Heart Fail. 2015 Feb;3(2):180-8
references.pmid: 25543971
references.citation: J Am Coll Cardiol. 2007 Aug 28;50(9):831-4
references.pmid: 17719467
references.citation: Eur Heart J. 2014 Oct 14;35(39):2733-79
references.pmid: 25173338
references.citation: J Am Coll Cardiol. 2014 Jul 8;64(1):83-99
references.pmid: 24998133
references.citation: Circulation. 2010 Sep 14;122(11):1130-3
references.pmid: 20837938
references.citation: N Engl J Med. 2011 Apr 28;364(17):1643-56
references.pmid: 21524215
references.citation: J Clin Invest. 2010 Oct;120(10):3520-9
references.pmid: 20811150
references.citation: J Cardiovasc Transl Res. 2009 Dec;2(4):483-92
references.pmid: 20560006